Celldex Therapeutics
celldex.comTotal trials
45
Active
7
Phase 3
5
Total enrollment
6,983
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| barzolvolimab | — | — | — | — | 9 | ||
| CDX-622 | — | — | — | — | — | 2 |
Next readouts
- 2026-05
- 2026-06
- 2026-10
- 2026-10
- 2027-03
- 2028-06
- 2028-09
Top conditions
- Breast Cancer5
- Ovarian Cancer5
- Chronic Spontaneous Urticaria5
- Colorectal Cancer4
- Bladder Cancer4
- Non-small Cell Lung Cancer4
- Head and Neck Cancer4
- Melanoma3
Frequently asked questions about Celldex Therapeutics
- How many clinical trials does Celldex Therapeutics have on ClinicalTrials.gov?
- Celldex Therapeutics is listed as the lead sponsor on 45 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Celldex Therapeutics's trials are in Phase 3?
- 5 of Celldex Therapeutics's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Celldex Therapeutics focus on?
- Celldex Therapeutics's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Ovarian Cancer, Chronic Spontaneous Urticaria, Colorectal Cancer, Bladder Cancer.
- When are Celldex Therapeutics's next clinical trial readouts?
- Celldex Therapeutics has 7 upcoming primary-completion readouts tracked here; the soonest is “A Study of Barzolvolimab in Patients With Atopic Dermatitis”, expected around 2026-05.